Cullinan Therapeutics Reports Q3 Financial Results and Cash Runway Extension
Cullinan Therapeutics (CGEM) reported its third-quarter financial results, noting a net loss of $49.4 million, a slight improvement compared to the $50.6 million loss recorded during the same period in the previous year. The company maintains a strong liquidity position with $313.8 million in cash, equivalents, and investments as of September 30, 2026. Based on its current operating plan, management expects these existing cash resources to provide an operational runway extending into 2029. Despite recent market volatility regarding clinical trial data delays for its arthritis therapy, the company continues to focus on its pipeline, including CLN-978 and REZILIENT3.
Tickers: $CGEM
Topics: cash_runway net_loss quarterly_earnings